Aim: This study aimed to perform an economic evaluation of Hemophilia ambulatory service delivery model (HASDM) comparing to the traditional home-episodic treatment model. Study Design: Tehran university of medical science, department pharmacoeconomics and pharmaceutical administration, between Jun 2016 and September 2018. Methods: A cost-minimization analysis (CMA) was conducted for evaluating potential savings of HASDM in comparison to the traditional home-episodic treatment model. The main cost of regular episodic service delivery, basic arm, consists of the cost of recombinant factor VIII (FVIII). In the Sadeghi et al.; JPRI, 31(6): 1-6, 2019; Article no.JPRI.53517 2 comparator arm, HASDM, the costs of HASDM for 1660 hemophilia A patients (HAPs) in Tehran were calculated. One-way sensitivity analysis was done to investigate the robustness of the results and to investigate the impact of uncertainty in the percentage of mistakes in bleeding sensation. Results: There were 1660 patients with severe Hemophilia A (PWSHA) in Tehran in 2018. The mean utilization of annual per patient FVIII was 44814 international units (IUs) in Iran. The total annual cost of FVIII concentrate for 1660 hemophilic patients in Tehran was estimated at $ 11,001,816. The cost of running HASDM, personal, and equipment is equal to $ 580,956. The cost of FVIII in HASDM would be $ 4,004,661. Therefore, the total cost of HASDM is estimated at $ 4,585,617. The amount of savings was $ 6,416,199. Sensitivity analysis indicated the robustness of the results up to 94.64% of the variation in the model parameters. Conclusions: HASDM, compared to episodic model, can save 58.32% of the funding for controlling bleeding in HAPs annually. This can save more than 38 times of HAPs annual cost over their lifetime.
INTRODUCTION
Hemophilia is a rare disease that causes bleeding as a result of deficiencies of coagulation factors. Hemophilia A (HA) and hemophilia B (HB) are the most common types of hemophilia, which are due to the low concentration of factor VIII and factor IX, respectively. HA is categorized in three levels according to coagulation factor activity, severe (<1%), moderate (1-5%), and mild (>5-30%) [1] . Hemophilia patients could have a good quality of life if they have access to adequate treatment; otherwise, they could suffer from joint destruction, disability or death [2] .
Iran has the ninth-largest population of hemophilic patients in the world [3] . The prevalence rate of HA and HB in Iran is estimated as 14 and 2.5 in 100,000 males, respectively [4] . Eighty two percent of hemophilia (HA) patients in Iran are suffering from factor VIII (FVIII) deficiency, and 60 percent of them are severe [3] . HA is a high-cost disease as it is a lifetime, and FVIII is a high-cost medicine [5] . All of HA patients are being treated with recombinant FVIII in Tehran.
The average annual health care cost for every patient was USD 15, 130 in Iran in 2018, 67% of it referred to medication [6] . All factor concentrates (medications), diagnostic tests and other health care services of patients with hemophilia A (PWHA) in Iran are covered by the ministry of health and health insurance organizations so that all facilities are free for the patients [3] .
Intra-articular bleeding is the most regular problem of HA [7] . Hemorrhage happens in 13% of muscle and 80% joints [8] . To manage muscle-skeletal bleeding in PWHA, two protocols are being used in PWHA; episodic (on-demand treatment) and prophylaxis. In episodic therapy, any bleeding episode could be managed by the patients in their home [9] . As in the other developing countries, episodic therapy is the most common therapeutic strategy to manage the joint bleeding episodes in Iran [3, 10] .The most part of the medical costs of PWHA is because of FVIII consumption [6] . Hence, governments should pay more attention to utilize their resources to improve hemophilia' treatment.
Episodic therapy is being managed based on the patients' perception [9] . It is showed that using FVIII based on patients' perception of bleeding can have a 63.6% error rate [11] . Indeed, they are taking FVIII mistakenly, as the sensation of pain in their joints could be a result of hemarthrosis [11] . This model of treatment can lead to a significant waste of economic resources. For solving this problem, we developed and introduced a Hemophilia Ambulatory Service Delivery Model (HASDM) for PWHA in Tehran, to manage the hemorrhagic conditions effectively [12] . Although we expect the health outcome of HASDM to be better than the episodic model in hemorrhage management, since we still do not have evidence for that, we assumed that its health outcomes are equal. Thus, the aim of this study was to perform a costminimization analysis of FVIII consumption of HASDM comparing to the traditional homeepisodic treatment model (without implementing ultrasonography).
METHODS
A cost-minimization analysis (CMA) was conducted for evaluating potential savings of HASDM as a telehealth intervention in comparison to the traditional episodic hometreatment model. All costs were calculated from the perspective of the health care payer. The prices were converted to US dollars based on the exchange rate of Iranian Rial to the US dollar in 2017 (one US dollar equals to 37,600 Iranian Rial). The cost data were collected from documented data in Iran food and drug administration (IFDA), Central Bank of Iran (CBI), and experts' opinions, where there was no recorded data. The main cost of traditional episodic service delivery, primary arm, consists of the cost of FVIII for 1660 HAPs in Tehran. In the comparator arm, HASDM, all running costs of HASDM for 1660 HAPs in Tehran were calculated. For this purpose, we first calculated the types and numbers of required personnel and equipment in HASDM, and then the annual costs of running HASDM plus the cost of FVIII were calculated. The details of the HASDM are presented elsewhere [12] . We used the following formula to calculate the cost savings due to the use of the HASDM model:
Where ∆C is the total saving cost, C1 is the cost of the traditional episodic service delivery model, and C2 is the total cost of HASDM. The total annual cost of FVIII resulting from traditional service care delivery model (C1) for the primary study, arms was calculated as follows:
C1= annual consumption of FVIII in Tehran * the price of FVIII
C2= Cost of HASDM + Cost of FVIII
A one-way sensitivity analysis was done to investigate the robustness of the results and to investigate the impact of uncertainty in the percentage of mistakes in bleeding sensation. This percentage was reduced to the extent which the delta cost becomes equal to zero. As the economic evaluation was done for one year, discounting was not applicable in this analysis.
RESULTS
According to the documented information in the Iranian Ministry of Health, there were 1660 hemophilic patients in Tehran in 2017. Based on the documented information in IFDA, the unit cost of FVIII was $ 0.15 and then the total annual cost of factor concentrate for 1660 HAPs in Tehran was estimated as follows:
1660 HAPs * Annual IU of FVIII per patient * Cost of one IU of FVIII = $ 11,001,816
In the HASDM arm, all of the 1660 HAPs are benefited from the new ambulatory service. The costs of human resources and equipment were calculated to measure the C HASDM ( The equipment does not need to change over the time. So, they were considered fixed costs and their depreciation rate was considered 15%. Indeed, the running cost of HASDM was waived for better comparison. The savings and related costs components of the CMA are shown in Table 2 .
Sensitivity analysis: In a one-way sensitivity analysis, we continuously reduced the patients' error rate (63.6%), which has been considered as the main cause of cost-wasting, until the delta cost reached to zero.
The results of sensitivity analysis confirmed that the delta cost will be zero if the patients' error rate (63.6%) is reduced by 94.64%. This means if the patients' error reduced to 3.38%, the total cost of HASDM would be equal to the traditional model, but at any rate above 3.4, the new model will be cost-saving. Therefore, HASDM is very robust and reliable and is not sensitive to the rate of patients' error by 94.64%.
DISCUSSION
The objective of this study was to perform a costminimization analysis of HASDM comparing to the traditional service care delivery. Without performing ultrasonography at the point of care, it was previously shown that in the traditional home therapy, 63.6% of patients' bleedings sensation was incorrect [11] . Thus, the same percentage of the medication (FVIII) was used incorrectly. Besides, hemophilia need continuous high-cost treatment [5] . The studies' results show the importance of HAPs' economic burden. Duncan et al. and Valentino et al. illustrated that the coagulation factors usage has been increased in some countries like Korea [13, 14] . The prescription compliance for the coagulation factor (CF) was reported at 80%, which might trigger in financial waste if CF was used incorrectly [15] . The mean per-patient annual direct cost of severe hemophilia was estimated at € 173,102, € 313,068, € 210,025, € 132,329, and € 116,963 for France, Germany, Italy, Spain, and the UK, respectively [16] . These are approximately 48, 79, 87, 65, and 34 times higher than the mean per-capita health expenditure in these countries [16] . Any new idea like HASDM could be useful for them to utilize their limited resources efficiently.
A practical and innovative HASDM was proposed for hemophilia A patient in Tehran in 2018 [12] to manage the wasteful medication and prevent losing economic resources. As the Iranian government, like many other developing countries, has economic limitation for implementing prophylaxis protocol, the on-demand protocol was considered for designing HASDM. The actual difference between HASDM and traditional home-episodic treatment is that in HASDM, the HAPs take medicine after implementing ultrasonography. Indeed, they do not use FVIII before effective diagnosis.
However, in the traditional model they take FVIII just according to their sensation without correct evaluation of their aura in their joints. HASDM is a home care model with five care centers in Tehran. In this model, the patients after bleeding sensation do not inject the FVIII immediately. Instead, they call one of the five centers to receive an accurate examination. After the arrival of a trained-care-giver to the patients' location and implementing the ultrasonography, he or she will send the result of ultrasonography online to the radiologists which are based in Care centers. The radiologists will diagnose and order medication if it would be the real bleeding. HASDM is designed so that the HAPs take their required medication/s in less than one hour. The details of this model including the type and number of human resources and equipment, the duration of one service according to treatment guidelines, location of the centers in the city, are presented elsewhere [12] .
Although HASDM is designed for HAPs in Tehran, but based on the number of patients, geographical distribution and facilities available, it can be adapted and used in other cities and countries; particularly in those in which episodic therapy is being used for controlling hemorrhage in HAPs. 18 6,416,199 58.32 In HASDM, ultrasonography was considered to distinguish the correct bleeding as a reliable method [13] . Although we supposed that the goal and outcomes of both models, HASDM and episodic, are similar in managing muscle-skeletal bleeding [9] , but we expect better health outcomes in HASDM because of more patients' satisfaction and fewer complications of FVIII. Nonetheless, as we have not documented evidence yet to prove this expectation, we assumed that both models have the same effects and did a CMA. Likewise, as the main impact of HASDM is on the utilization of FVIII, we assumed that the costs of diagnostic and laboratory services are the same in both models.
Other cost savings, such as a reduction in the rate of inhibitory patients, preventing drug smuggling, and direct non-medical costs, were also not considered in our analysis. This means that, if they were considered, they would have significantly increased the amount of cost-saving. Nevertheless, it is illustrated that HASDM could improve the efficiency of treatment of bleeding episodes significantly.
As the health expenditure are increasing in all countries, there is increasing pressure on health care managers to improve efficiency and quality of health care delivery. Our study shows that the episodic model of health care delivery for managing hemorrhage is not an efficient manner. One of the sources of inefficiency in this model is wrong sensation of bleeding in HAPs. This could be responsible for more than 63% of the wastage in this model ( Table 2 ). The second source of inefficiency could be attributed to the rate of development of FVIII inhibitors in HAPs. Several studies have showed the relationship between the frequency of treating with FVIII and increasing the risk of development of FVIII inhibitors [17] [18] [19] [20] . As the number of injection FVIII will decrease in HASDM, it is expected that HASDM can reduce both sources of inefficiency more than 60%. Table 1 show that HASDM can run at 5.28% of the cost of the FVIII in episodic model. In fact, by 5.28% of expenses allocated to the hemophilic patients in Tehran, the annual costs can be reduced by 58.32% in each year. Considering the fact that hemophilia is a lifelong disorder (around 65 years in Iran), the total savings per patient would be about 38 times their annual cost.
The figures in
Sensitivity analysis is showing the robustness of the outcomes by about 94.64%. The source of the HASDM could be supplied by the substitution of the traditional model. During evaluating the feasibility and reliability of the HASDM, it was shown, the high range of patients' compliance regarding this alternative, moreover, clinicians, and health politicians proved its feasibility.
The results of sensitivity analysis confirmed that HASDM is highly robust and reliable.
CONCLUSION
HASDM, compared to episodic model, can save 58.32% of the funding for controlling bleeding in HAPs annually. This can save more than 38 times of HAPs annual cost over their lifetime.
This health care delivery model can increase the efficiency of managing hemorrhage in HAPs through two mechanism; correct diagnosis of bleeding in HAPs and decreasing the rate of development of FVIII inhibitors in HAPs.
